Sort   by:  
 Page size 
UnknownColon cancer subtypes: concordance, effect on survival and selection of the most representative preclinical models.
Multiple gene-expression-based subtypes have been proposed for the molecular subdivision of colon cancer in the last decade. We aimed to cross-validate these classifiers to explore their concordance and their power to predict survival. A gene-chip-based database comprising 2,166 samples from 12 inde...
S-EPMC5111107 | biostudies-literature
UnknownA comprehensive overview of targeted therapy in metastatic renal cell carcinoma.
Chemotherapy and immunotherapy failed to deliver decisive results in the systemic treatment of metastatic renal cell carcinoma. Agents representing the current standards operate on members of the RAS signal transduction pathway. Sunitinib (targeting vascular endothelial growth factor), temsirolimus ...
S-EPMC3434473 | biostudies-literature
UnknownIntratumoral T-cell and B-cell receptor architecture associates with distinct immune tumor microenvironment features and clinical outcomes of anti-PD-1/L1 immunotherapy.

Background

Effective cooperation between B-cells and T-cells within the tumor microenvironment may lead to the regression of established tumors. B-cells and T-cells can recognize tumor antigens with exquisite specificity via their receptor complexes. Nevertheless, whether a diverse intratumo...
S-EPMC10445359 | biostudies-literature
UnknownValidation of RNAi Silencing Efficiency Using Gene Array Data shows 18.5% Failure Rate across 429 Independent Experiments.
No independent cross-validation of success rate for studies utilizing small interfering RNA (siRNA) for gene silencing has been completed before. To assess the influence of experimental parameters like cell line, transfection technique, validation method, and type of control, we have to validate the...
S-EPMC5056990 | biostudies-literature
UnknownDynamic classification using case-specific training cohorts outperforms static gene expression signatures in breast cancer.
The molecular diversity of breast cancer makes it impossible to identify prognostic markers that are applicable to all breast cancers. To overcome limitations of previous multigene prognostic classifiers, we propose a new dynamic predictor: instead of using a single universal training cohort and an ...
S-EPMC4354298 | biostudies-literature
UnknownHistopathology and proteomics are synergistic for high-grade serous ovarian cancer platinum response prediction.
Patients with High-Grade Serous Ovarian Cancer (HGSOC) exhibit varied responses to treatment, with 20-30% showing de novo resistance to platinum-based chemotherapy. While hematoxylin-eosin (H&E)-stained pathological slides are used for routine diagnosis of cancer type, they may also contain diagnost...
S-EPMC11762732 | biostudies-literature
UnknownPALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer.
PARP inhibitors were recently approved for treatment of molecularly-defined subsets of metastatic castrate-resistant prostate cancer (mCRPC) patients. Although the PARP inhibitor olaparib was approved for use in patients with a mutation in one of fourteen genes, the mutation frequency of the genes v...
S-EPMC9242979 | biostudies-literature
UnknownHistopathology and proteomics are synergistic for High-Grade Serous Ovarian Cancer platinum response prediction.
Patients with High-Grade Serous Ovarian Cancer (HGSOC) exhibit varied responses to treatment, with 20-30% showing de novo resistance to platinum-based chemotherapy. While hematoxylin-eosin (H&E) pathological slides are used for routine diagnosis of cancer type, they may also contain diagnosti...
S-EPMC11177907 | biostudies-literature
UnknownA major genetic accelerator of cancer diagnosis: rs867228 in FPR1.
Not available
S-EPMC7801119 | biostudies-literature
UnknownIdentification of an <i>ERCC2</i> mutation associated mutational signature of nucleotide excision repair deficiency in targeted panel sequencing data.
Next generation sequencing based mutational signatures are frequently used to identify tumors with specific DNA repair deficiencies for targeted therapeutic strategies. Although mutational signatures are most commonly derived from whole exome (WES) or whole genome sequencing (WGS) data, more patient...
S-EPMC12934613 | biostudies-literature
Sort   by:  
 Page size